KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2025)

Recursion Pharmaceuticals' Cash from Investing Activities history spans 6 years, with the latest figure at -$1.2 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 100.45% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$16.9 million, down 106.49%, while the annual FY2025 figure was -$16.9 million, 106.49% down from the prior year.
  • Cash from Investing Activities reached -$1.2 million in Q4 2025 per RXRX's latest filing, up from -$2.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $275.5 million in Q4 2024 to a low of -$193.9 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is $7.7 million, with a median of -$4.4 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: crashed 15828.21% in 2021, then skyrocketed 11171.38% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$52.2 million in 2021, then skyrocketed by 84.73% to -$8.0 million in 2022, then skyrocketed by 68.82% to -$2.5 million in 2023, then surged by 11171.38% to $275.5 million in 2024, then plummeted by 100.45% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Cash from Investing Activities are -$1.2 million (Q4 2025), -$2.5 million (Q3 2025), and -$5.8 million (Q2 2025).